List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 974 studies with search of: "Doxorubicin"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Conditions: Cancer;   Carcinoma;   Fallopian Tube Cancer;   Gynecological Malignancies;   Metastases;   Oncology;   Ovarian Cancer;   Solid Tumors;   Tumors
Interventions: Drug: Part 2, Cohort A: AMG 386 MTD Part 1 + Liposomal doxorubicin;   Drug: B1: AMG 386 10 mg/kg + Topotecan;   Drug: B2: AMG 386 3mg/kg + Topotecan;   Drug: A1: AMG 386 10 mg/kg + Liposomal doxorubicin;   Drug: A2: AMG 386 3mg/kg + Liposomal doxorubicin;   Drug: Part 2, Cohort B: AMG 386 MTD part 1 + Topotecan
2 Recruiting A Scandinavian Sarcoma Group Protocol for Patients With High-Risk Soft Tissue Sarcoma of the Extremities and Trunk Wall
Conditions: Soft Tissue Sarcoma;   Non Metastatic Disease
Interventions: Drug: doxorubicin , ifosfamide;   Drug: doxorubicin, ifosfamide;   Drug: doxorubicin, ifosfamide;   Drug: doxorubicin, ifosfamide
3 Recruiting A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-Tissue Sarcoma
Condition: Soft Tissue Sarcoma
Interventions: Drug: Palifosfamide Tris and Doxorubicin;   Drug: Doxorubicin
4 Completed Vincristine, DOXIL® (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Conditions: Myeloma Proteins;   Multiple Myeloma;   Myeloma;   M-Protein
Intervention: Drug: Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)
5 Completed Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer
Condition: Primary Breast Cancer
Interventions: Drug: Adriamycin (Doxorubicin), Docetaxel, Tamoxifen;   Drug: Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid
6 Active, not recruiting Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: DOXIL/CAELYX (pegylated liposomal doxorubicin) in combination with VELCADE (bortezomib) vs. VELCADE (bortezomib)monotherapy.
7 Recruiting A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Liposomal Doxorubicin/Melphalan/Bortezomib
8 Recruiting Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer
Condition: Early-Stage Breast Cancer
Interventions: Drug: genomically-guided treatment: Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC);   Drug: non-genomically-guided treatment: Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)
9 Recruiting Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)
Condition: Prostate Cancer
Interventions: Drug: Thalidomide;   Drug: Doxil® (doxorubicin HCL liposome injection)
10 Recruiting Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients
Condition: Ewing's Sarcoma
Interventions: Drug: Vincristine;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Dexrazoxane;   Biological: ImmTher
11 Recruiting Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients
Condition: Breast Cancer
Interventions: Drug: Taxotere;   Drug: Adriamycin/Cytoxan;   Drug: docetaxol;   Drug: doxorubicin
12 Active, not recruiting Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Pegylated liposomal doxorubicin (Caelyx);   Drug: Epirubicin
13 Recruiting Study of PXD101 and Doxorubicin to Treat Soft Tissue Sarcomas
Condition: Soft Tissue Sarcomas
Intervention: Drug: PXD101 + doxorubicin
14 Active, not recruiting A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma
Conditions: Sarcoma, Kaposi;   HIV Infections
Interventions: Drug: Doxorubicin hydrochloride (liposomal);   Drug: Bleomycin sulfate;   Drug: Vincristine sulfate;   Drug: Doxorubicin hydrochloride
15 Active, not recruiting BIG 02/98 Docetaxel - Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: Doxorubicine + docetaxel sequential;   Drug: doxorubicine + cyclophosphamide sequential;   Drug: doxorubicine + cyclophosphamide combined;   Drug: doxorubicine + docetaxel combined
16 Not yet recruiting A Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Doxorubicin Hydrochloride Liposome Injection- Test;   Drug: Doxorubicin Hydrochloride Liposome Injection- Reference
17 Recruiting Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone;   Drug: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
18 Not yet recruiting A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection in Patients With Ovarian Cancer
Condition: Ovarian Carcinoma
Interventions: Drug: Liposomal Doxorubicin Hydrochloride;   Drug: Liposomal Doxorubicin Hydrochloride Injection
19 Recruiting Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
Conditions: Solid Tumor;   Urethral Cancer
Interventions: Drug: Bortezomib;   Drug: Gemcitabine;   Drug: Doxorubicin
20 Recruiting Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer
Conditions: Epithelial Ovarian Carcinoma;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma
Intervention: Drug: SB-485232 (interleukin 18), pegylated liposomal doxorubicin

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services